Logo image of MIRO

MIROMATRIX MEDICAL INC (MIRO) Stock Fundamental Analysis

NASDAQ:MIRO - US60471P1084 - Common Stock

3.39 USD
+0.02 (+0.59%)
Last: 12/12/2023, 8:00:01 PM
3.39 USD
0 (0%)
After Hours: 12/12/2023, 8:00:01 PM
Fundamental Rating

3

MIRO gets a fundamental rating of 3 out of 10. The analysis compared the fundamentals against 54 industry peers in the Life Sciences Tools & Services industry. MIRO scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. MIRO is valued quite expensive, but it does show an excellent growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

MIRO had negative earnings in the past year.
In the past year MIRO has reported a negative cash flow from operations.
MIRO Yearly Net Income VS EBIT VS OCF VS FCFMIRO Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 2022 -10M -20M -30M

1.2 Ratios

Looking at the Return On Assets, with a value of -117.04%, MIRO is doing worse than 95.08% of the companies in the same industry.
MIRO has a Return On Equity of -176.38%. This is amonst the worse of the industry: MIRO underperforms 88.52% of its industry peers.
Industry RankSector Rank
ROA -117.04%
ROE -176.38%
ROIC N/A
ROA(3y)-102.22%
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
MIRO Yearly ROA, ROE, ROICMIRO Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 2022 0 100 -100 200

1.3 Margins

MIRO's Gross Margin of 47.92% is in line compared to the rest of the industry. MIRO outperforms 54.10% of its industry peers.
The Profit Margin and Operating Margin are not available for MIRO so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 47.92%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
MIRO Yearly Profit, Operating, Gross MarginsMIRO Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 2022 0 -10K -20K -30K -40K -50K

More info and screens

4

2. Health

2.1 Basic Checks

MIRO does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, MIRO has more shares outstanding
The debt/assets ratio for MIRO has been reduced compared to a year ago.
MIRO Yearly Shares OutstandingMIRO Yearly Shares OutstandingYearly Shares Outstanding 2019 2020 2021 2022 5M 10M 15M 20M
MIRO Yearly Total Debt VS Total AssetsMIRO Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2019 2020 2021 2022 20M 40M 60M

2.2 Solvency

Based on the Altman-Z score of -3.73, we must say that MIRO is in the distress zone and has some risk of bankruptcy.
MIRO has a worse Altman-Z score (-3.73) than 88.52% of its industry peers.
MIRO has a Debt/Equity ratio of 0.03. This is a healthy value indicating a solid balance between debt and equity.
MIRO's Debt to Equity ratio of 0.03 is in line compared to the rest of the industry. MIRO outperforms 59.02% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.03
Debt/FCF N/A
Altman-Z -3.73
ROIC/WACCN/A
WACC12.72%
MIRO Yearly LT Debt VS Equity VS FCFMIRO Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2019 2020 2021 2022 0 20M -20M 40M

2.3 Liquidity

A Current Ratio of 3.46 indicates that MIRO has no problem at all paying its short term obligations.
The Current ratio of MIRO (3.46) is comparable to the rest of the industry.
MIRO has a Quick Ratio of 3.46. This indicates that MIRO is financially healthy and has no problem in meeting its short term obligations.
MIRO has a better Quick ratio (3.46) than 62.30% of its industry peers.
Industry RankSector Rank
Current Ratio 3.46
Quick Ratio 3.46
MIRO Yearly Current Assets VS Current LiabilitesMIRO Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2019 2020 2021 2022 10M 20M 30M 40M 50M

More info and screens

7

3. Growth

3.1 Past

MIRO shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 17.99%, which is quite good.
MIRO shows a strong growth in Revenue. In the last year, the Revenue has grown by 3100.00%.
Measured over the past years, MIRO shows a very strong growth in Revenue. The Revenue has been growing by 56.05% on average per year.
EPS 1Y (TTM)17.99%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%35.14%
Revenue 1Y (TTM)3100%
Revenue growth 3Y56.05%
Revenue growth 5YN/A
Sales Q2Q%0%

3.2 Future

MIRO is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 19.77% yearly.
MIRO is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 490.87% yearly.
EPS Next Y32.47%
EPS Next 2Y18.41%
EPS Next 3Y7.54%
EPS Next 5Y19.77%
Revenue Next Year-6.67%
Revenue Next 2Y-5.13%
Revenue Next 3Y-3.45%
Revenue Next 5Y490.87%

3.3 Evolution

The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
MIRO Yearly Revenue VS EstimatesMIRO Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2B 4B 6B
MIRO Yearly EPS VS EstimatesMIRO Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 0 2 4 6 8 10

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

MIRO reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for MIRO. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
MIRO Price Earnings VS Forward Price EarningsMIRO Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
MIRO Per share dataMIRO EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 -0.5 -1

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y18.41%
EPS Next 3Y7.54%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for MIRO!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

MIROMATRIX MEDICAL INC

NASDAQ:MIRO (12/12/2023, 8:00:01 PM)

After market: 3.39 0 (0%)

3.39

+0.02 (+0.59%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryLife Sciences Tools & Services
Earnings (Last)11-14 2023-11-14/amc
Earnings (Next)N/A N/A
Inst Owners22.32%
Inst Owner Change-7.87%
Ins Owners108.14%
Ins Owner Change0%
Market Cap92.95M
Analysts80
Price Target3.19 (-5.9%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)3.41%
Min EPS beat(2)-12.04%
Max EPS beat(2)18.86%
EPS beat(4)2
Avg EPS beat(4)3.41%
Min EPS beat(4)-12.04%
Max EPS beat(4)18.86%
EPS beat(8)3
Avg EPS beat(8)-11.37%
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)2
Avg Revenue beat(2)180.11%
Min Revenue beat(2)180.11%
Max Revenue beat(2)180.11%
Revenue beat(4)4
Avg Revenue beat(4)6622.69%
Min Revenue beat(4)180.11%
Max Revenue beat(4)25950.4%
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)-65.28%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)99900%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 96.83
P/FCF N/A
P/OCF N/A
P/B 5.98
P/tB 5.98
EV/EBITDA N/A
EPS(TTM)-1.14
EYN/A
EPS(NY)-0.87
Fwd EYN/A
FCF(TTM)-0.89
FCFYN/A
OCF(TTM)-0.89
OCFYN/A
SpS0.04
BVpS0.57
TBVpS0.57
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -117.04%
ROE -176.38%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 47.92%
FCFM N/A
ROA(3y)-102.22%
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0.04
Health
Industry RankSector Rank
Debt/Equity 0.03
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 19.83%
Cap/Sales 23.96%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 3.46
Quick Ratio 3.46
Altman-Z -3.73
F-Score3
WACC12.72%
ROIC/WACCN/A
Cap/Depr(3y)718.11%
Cap/Depr(5y)N/A
Cap/Sales(3y)3872.75%
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)17.99%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%35.14%
EPS Next Y32.47%
EPS Next 2Y18.41%
EPS Next 3Y7.54%
EPS Next 5Y19.77%
Revenue 1Y (TTM)3100%
Revenue growth 3Y56.05%
Revenue growth 5YN/A
Sales Q2Q%0%
Revenue Next Year-6.67%
Revenue Next 2Y-5.13%
Revenue Next 3Y-3.45%
Revenue Next 5Y490.87%
EBIT growth 1Y0.1%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year15.34%
EBIT Next 3Y-21.4%
EBIT Next 5YN/A
FCF growth 1Y-135.06%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-139.27%
OCF growth 3YN/A
OCF growth 5YN/A